Vanoglipel (DA-1241)

May 14, 2026: MetaVia Inc. (NASDAQ: MTVA) reported Q1 2026 financial results and provided a catalyst update for its cardiometabolic pipeline.

DA-1726 (obesity, Phase 1): The company highlighted dosing of the first patient (April 2026) in Part 3 of its Phase 1 trial in obese, otherwise healthy adults, following March 2026 IRB approval. Part 3 includes two 16-week titration cohorts evaluating a one-step titration to 48 mg and a two-step titration to 64 mg; data are expected in Q4 2026. MetaVia also referenced prior January 2026 results from an 8-week non-titrated 48 mg multiple-ascending-dose cohort showing 9.1% weight loss, statistically significant waist circumference reductions, improvements in glucose control, and reductions in liver stiffness with favorable safety/tolerability. Additional 48 mg Phase 1 data, including exploratory noninvasive liver assessments, are slated for presentation at EASL Congress 2026 (poster announced May 2026).

Vanoglipel/DA-1241 (MASH): The company said it is working to schedule an end-of-Phase 2 FDA meeting; it also noted IP portfolio updates and positive AI-modeling results from a collaboration with Syntekabio supporting development in MASH (and potentially type 2 diabetes).